In this study, the marked reduction in PD-L1 expression in CHL-GCS-IO NPs-treated tumors suggested that PTT, in combination with ferroptosis, disrupted immune tolerance, allowing for more-effective CD8+ T-cell-mediated tumor cell killing. The gene discussed is CD8A; the disease is neoplasm.